Log in
Enquire now
Roivant Sciences

Roivant Sciences

Roivant Sciences is a pharmaceutical company founded by Vivek Ramaswarmy. It focuses on the discovery and development of late-stage drug candidates.

OverviewStructured DataIssuesContributors

Contents

roivant.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Artificial Intelligence (AI)
Artificial Intelligence (AI)
Drug discovery
Drug discovery
Biopharmaceutical
Biopharmaceutical
Pharmaceutical industry
Pharmaceutical industry
Biotechnology
Biotechnology
Biology
Biology
Healthcare
Healthcare
...
Location
Boston
Boston
0
Basel
Basel
0
New York City
New York City
0
B2X
B2C
B2C
0
B2B
B2B
CEO
Matthew Gline
Matthew Gline
AngelList URL
angel.co/roivant-sciences/
Pitchbook URL
pitchbook.com/profiles...115307-11
Legal Name
Roivant Sciences Ltd.0
Number of Employees (Ranges)
201 – 5000
Email Address
careers@roivant.com0
info@roivant.com0
ir@roivant.com0
Number of Employees
8630
Full Address
451 D Street Boston, MA 02210 United States0
151 W 42nd St, 15th Floor, New York, New York 10036, US0
Viaduktstrasse 8 4051 Basel Switzerland0
CIK Number
1,635,0880
Place of Incorporation
Bermuda
Bermuda
0
Investors
Novaquest Capital Management
Novaquest Capital Management
Suvretta Capital
Suvretta Capital
0
QVT Financial
QVT Financial
Founders Fund
Founders Fund
Viking Global Investors
Viking Global Investors
SoftBank Vision Fund
SoftBank Vision Fund
Dexcel Pharma.
Dexcel Pharma.
0
RTW Investments LLC
RTW Investments LLC
IRS Number
981,173,9440
Founded Date
2014
Total Funding Amount (USD)
1,300,000,000
Latest Funding Round Date
November 13, 2018
Stock Symbol
ROIV0
Exchange
Nasdaq
Nasdaq
Glassdoor ID
1910951
Board of Directors
‌
Melissa Epperly
0
‌
Hiroshi Nomura
0
‌
James C. Momtaze
0
Andrew Lo
Andrew Lo
0
‌
Keith Manchester
0
Vivek Ramaswamy
Vivek Ramaswamy
0
Matthew Gline
Matthew Gline
0
CFO
Richard Pulik
Richard Pulik
Key People
Humphrey Gardner
Humphrey Gardner
Huafeng Xu
Huafeng Xu
Pamela Carroll
Pamela Carroll
Benjamin Zimmer
Benjamin Zimmer
Woody Sherman
Woody Sherman
Alex Gasner
Alex Gasner
Amy Mahery
Amy Mahery
Deya Corzo
Deya Corzo
...
Latest Postmoney Valuation
7,000,000,000
CAGE Code
SFDW60
COO
Matt Maisak
Matt Maisak
Wellfound ID
roivant-sciences
Country
United States
United States
0
Switzerland
Switzerland
0
Headquarters
Hamilton, Bermuda
Hamilton, Bermuda

Other attributes

Company Operating Status
Active
Strategic Partnerships
QB3 Garage @ UCSF & Berkeley
QB3 Garage @ UCSF & Berkeley
Invested in
Medallion
Medallion
Datavant
Datavant
SIC Code
2,8340
Ticker Symbol
ROIV0
Wikidata ID
Q28135221

Roivant was founded in 2014 by former hedgefund analyst Vivek Ramaswarmy on the basis that the company will attempt to buy late stage pipeline molecules that are abandoned or shelved by other pharma companies.

Funding

The company has raised in excess of $2.7bn, $1bn of which originates from the Softbank New Vision fund. The company is headquartered in Basel, Switzerland but is run under a Bermuda holding entity for tax efficiency, similar to how an investment fund is structured.

Company strategy

Roivant's first acquisition was an Alzheimers drug originally developed by GlaxoSmithKline sold to Axovant (subcompany owned by Roivant) for $20m. The drug, Interpirdine, an H5-ST2A receptor agonist is in Phase 2B, despite early set backs when it failed to meet its clinical end points in the original phase 2 trial. Gsk licensed the drug to Roivant based on, what is likely a risk adjusted NPV and a review of against other pipeline drugs in which a gated investment strategy makes necessary a trade off in investment dollars for drugs that have the highest estimated peak sales and corresponding r-NPV. GSK, for instance, may want to focus the estimated $1bn it takes to bring the molecule to market on other molecules in its pipeline and hence wanted to offload Interpirdine and recoup as much of its original investment into pre-clinical and other R&D. Roivant is betting that the probability of passing the acquired molecules as higher than the originator pharmaceutical and that additional FDA approvals for indications can be attained.

Company structure

Roivant is a holding company for a number of subcompanies called 'Vants' controlled by Roivant but operated almost as individual and autonomous companies. In a competitor such as Novartis or GlaxoSmithKline, the drugs would be operated within a brand franchise rather than autonomous entities.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Roivant Sciences

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.